// App-Quantinova.ai

SU-OR39 : LNP023: A Novel Oral Complement Alternative Pathway Factor B Inhibitor Safely and Effectively Reduces Proteinuria in C3 Glomerulopathy

Researchers

Presenter

  • Wong EdwinKwan Soon

Principal Investigators

  • Praga Manuel

  • Nester CarlaMarie

  • Daina Erica

  • Remuzzi Giuseppe

  • Nidamarthy Prasanna Kumar

  • End PeterR C

  • Milojevic JulieM

  • Biondani Andrea

  • Trapani AngeloJ

  • Webb Nicholas

  • Junge Dr Guido

Medical Centers

  • Royal Victoria Infirmary Newcastle upon Tyne Newcastle upon Tyne United Kingdom

  • Hospital Doce de Octubre, Madrid, Spain

  • Istituto di Ricerche Farmacologiche Mario Negri IRCCS

  • Novartis Pharma AG, Basel, Basel-Stadt, Switzerland

Locations

  • United Kingdom

  • Spain

  • United States

  • Italy

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • C3 glomerulopathy

  • Albuminuria

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved